Save Cures

Patients need real solutions for lowering drug costs, not political bills that
jeopardize patient access to life-saving medicines.
Save Cures
Meet Lisa
Meet Lisa: Finding Purpose in Gene Therapy
Meet Mark: Advocating For Access to Approved Therapies
Meet Mark: Advocating For Access to Approved Therapies
Meet Sanath: Creating Opportunities for Rare Disease Treatments
Meet Sanath: Creating Opportunities for Rare Disease Treatments

We need our elected leaders to lower patients’ out-of-pocket cost for innovative prescription drugs.

Unfortunately, Congress is considering radical price-setting bills, similar to H.R. 3, that would allow the policies of foreign governments to set the standard of care for American patients. These foreign policies lead to rationed care and limit access to prescription medicines. These bills could:

  • Drastically limit patient access to vital medicines and therapies that are needed to treat cancer, Alzheimer’s, and other devastating diseases.
  • Disrupt the doctor-patient relationship by empowering bureaucrats to get between patients and the medicines they need; and
  • Do nothing to lower what most seniors and patients are forced to pay for prescription drugs.

Patients need real solutions for lowering drug costs, not political bills that jeopardize patient access to life-saving medicines.

  • According to an analysis by Vital Transformation, there would have been 61 fewer treatments developed over 10 years if H.R. 3 were law today.
  • Even Congress’s own budget experts warned that the bill will lead to fewer treatments being developed in the coming years.
 
 
H.R. 3 Resources
Podcast
Episode 7
Sickle Cell Saviors
Image
Ted Love


Need a dose of inspiration in a time of national tragedy? A remarkable biotech breakthrough from Global Blood Therapeutics offers fresh hope to patients living with sickle-cell disease.

Subscribe
Videos
health-followthepill
Why are seniors paying so much out of pocket for their medicines?
Drug-Cost-Debate
Understanding Your Drug Costs: Follow the Pill
How Decisions in Washington Impact Biotech Investment
How Decisions in Washington Impact Biotech Investment
Sorry… This form is closed to new submissions.